Skip to search formSkip to main contentSkip to account menu

epristeride

Known as: 17-N-t-butylcarboxamide androst-3,5-diene-3-carboxylic acid 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

5-alpha Reductase InhibitorsAndrostadienes

Narrower (2)

ONO-9302SK&F-105657

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2
2002
2002
[The clinical efficacy of epristeride in the treatment of benign prostatic hyperplasia].
OBJECTIVES To estimate the clinical safety, efficacy of Epristeride in the treatment of benign prostatic hyperplasia (BPH… 
2001
2001
Inhibition of regrowth of prostatic glandular cells by epristeride.
AIM To evaluate the ability of epristeride to inhibit the prostatic glandular regrowth. METHODS Normal rats were castrated… 
2001
2001
Inhibition of cultured rat prostatic epithelial cell growth by epristeride in vitro.
AIM To study the molecular mechanism of rat prostate atrophy induced by epristeride. METHODS MTT test was used to determine the… 
2000
2000
[Pharmacokinetics of epristeride in rats and beagle dogs].
AIM To study the pharmacokinetics of epristeride (EPR) in rats and Beagle dogs. METHODS The concentrations of EPR in biological… 
1999
1999
Reversible long-term toxicity of epristeride in beagle dogs.
Epristeride (17beta-N-t-butylcarboxamide-androst-3, 5-diene-3-carboxylic acid) is an uncompetitive inhibitor of steroid 5alpha… 
1999
1999
A Novel Class of Inhibitors for Human Steroid 5α-Reductase : Phenoxybenzoic Acid Derivatives. I
In a search for novel nonsteroidal inhibitors of human prostatic 5α-reductase, we found a new series of phenoxybenzoic acid… 
1998
1998
Epristeride SmithKline Beecham.
Epristeride is a transition-state, noncompetitive steroid 5-alpha-reductase inhibitor under development by SmithKline Beecham for… 
1998
1998
Mutagenicity tests on epristeride in vitro and in vivo.
AIM To evaluate the genetic effects of epristeride (Epr), a new prospective drug for treating benign prostatic hyperplasia… 
1997
1997
Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats.
ONO-9302 [epristeride; (-)-17beta-(tert-butylcarbamoyl)androsta-3,5-diene-3-carboxy lic acid] is a novel inhibitor of steroid… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)